New-generation basal insulin launched

Manama : Novo Nordisk has launched Tresiba a new generation basal insulin in Bahrain yesterday. 

Tresiba is a once-daily basal insulin for people with diabetes that achieves equivalent reductions in blood glucose levels, with a lower risk of nocturnal hypoglycaemia versus insulin glargine. It allows flexibility in day-to-day dosing time.

One of the key challenges with insulin therapy is the risk of hypoglycaemia, when blood glucose levels fall to lower than normal, causing dizziness and confusion, unconsciousness and sometimes even death. Research shows that fears and concerns about hypoglycaemia can interfere with achieving optimal glycaemic control in people with diabetes using insulin. Hypoglycaemia that occurs at night is of particular concern for people living with diabetes, as it is difficult to detect.

“Maintaining good blood glucose control with insulin treatment can be challenging due to concerns over hypoglycaemia and night-time hypoglycaemia in particular. Tresiba has shown less risk of nocturnal hypoglycaemia than the most widely used basal insulin,” said Vikrant Shrotriya, VP Gulf, Novo Nordisk.

Tresiba can be administered at any time of the day, offering flexible dosing when needed.